查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1643909

全球靜脈支架市場 - 2025-2033

Global Venous Stents Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球靜脈支架市場規模達12.4億美元，預計2033年將達26.2億美元，2025-2033年預測期間複合年成長率為8.5%。

靜脈支架是可擴張的金屬網管，可對阻塞或狹窄的靜脈壁施加壓力，並作為支架以保持靜脈暢通。它們通常放置在腹部、胸部和腿部較大的中央靜脈中。靜脈支架用於治療慢性深部靜脈栓塞（DVT）、血液透析/動靜脈瘻管、梅-瑟納症候群、胡桃夾症候群和血栓後症候群。 DVT 被定義為在一根大的深層靜脈形成血塊，將血液從腿部回流到心臟和肺部的情況。

市場動態：

驅動程式和限制

科技進步的崛起

技術進步透過提高支架手術的有效性、安全性和壽命來推動全球靜脈支架市場的成長。鎳鈦諾等生物相容性合金可增強靈活性和耐用性，減少併發症。藥物洗脫支架釋放藥物以防止再狹窄，從而減少重複手術的需要。自擴張式支架和球囊擴張式支架在微創手術中易於使用，從而實現更快的恢復時間和更好的患者體驗。

此外，支架設計的技術進步是不可避免的，並且可能超過資料收集的速度。目前的支架主要是雷射切割鎳鈦合金設計，也有一些開放式和混合式設計。未來的設計可能會結合藥物塗層和替代設計來影響泊松效應或流動等因素。了解導致通暢喪失的因素以及支架血栓形成和閉塞的生物機制對於預防支架失效至關重要。

併發症和再狹窄的風險

由於併發症和再狹窄的風險，全球靜脈支架市場正面臨一些併發症，這引發了有關靜脈支架手術的長期有效性和安全性的問題。儘管支架技術取得了進步，但支架血栓、感染或靜脈重新狹窄等障礙仍然存在，可能會導致進一步的手術、長時間的恢復或一些手術干預。這種恐懼有時會針對患者甚至醫療保健提供者，有時不考慮靜脈支架作為一種選擇。因此，它的採用率相當緩慢，並限制了整體市場潛力。這推動了靜脈測試在醫療保健行業的出現和接受度。

有關此報告的更多詳細資訊 - 索取樣本

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 科技進步的崛起
    • 限制
      • 併發症和再狹窄的風險
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章：依產品類型

  • 覆膜支架
  • 自膨式支架
  • 球囊擴張支架
  • 裸支架

第 7 章：按材料

  • 鎳鈦諾
  • 金屬支架
  • 不銹鋼
  • 聚合物
  • 其他

第 8 章：按申請

  • 深部靜脈血栓 (DVT)
  • 慢性靜脈功能不全（CVI）
  • 肺栓塞（PE）
  • 腫瘤閉塞
  • 其他

第 9 章：最終用戶

  • 醫院
  • 專科診所
  • 門診手術中心

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Medtronic Plc
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售
    • 財務概覽
      • 公司收入
      • 地域收入分成
      • 收入預測
    • 主要進展
      • 併購
      • 主要產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Boston Scientific Corporation
  • Cook Medical
  • Terumo Corporation
  • Becton, Dickinson and Company (BD)
  • Abbott Laboratories
  • Cordis Corporation(Cardinal Health)
  • Vesper Medical
  • Bentley
  • Optimed Medizinische Instrumente GmbH
  • Similar data will be provided for each market player.
  • 內多洛吉克斯
    • 管道產品說明
    • 產品關鍵績效指標 (KPI)
    • 主要活動
    • 市場進入時間表
    • 產品滲透率
    • 銷售估算與預測
  • 環球醫療
  • 主動脈有限公司
  • 操作內
  • 喬泰克有限公司
  • 將為每個市場參與者提供類似的資料。

第 12 章：附錄

簡介目錄
Product Code: MD8057

The global venous stents market reached US$ 1.24 billion in 2024 and is expected to reach US$ 2.62 billion by 2033, growing at a CAGR of 8.5% during the forecast period 2025-2033.

Venous stents are expandable metal mesh tubes which apply pressure to walls of blocked or narrowed veins and act as a scaffold to keep the veins open. They are usually placed in the bigger central veins located in the abdomen, chest, and legs. Venous stents are used to treat chronic deep vein thrombosis (DVT), hemodialysis/arteriovenous fistulae, May-Thurner syndrome, Nutcracker syndrome, and post-thrombotic syndrome. DVT is defined as the condition where a blood clot develops in one of the large, deep veins, which brings back blood from the leg to the heart and lungs.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

Technological advancements are driving the global venous stents market growth by improving the effectiveness, safety, and longevity of stenting procedures. Biocompatible alloys like nitinol enhance flexibility and durability, reducing complications. Drug-eluting stents release medication to prevent restenosis, reducing the need for repeat procedures. Self-expanding and balloon-expandable stents provide ease of use during minimally invasive surgeries, allowing quicker recovery times and better patient experiences.

Moreover, technological advancements in stent design are inevitable and likely to outpace data collection. Current stents are mainly laser-cut nitinol designs, with some open and hybrid designs. Future designs may incorporate drug coating and alternative designs to influence factors like the Poisson effect or flow. Understanding factors driving patency loss and the biological mechanism of stent thrombosis and occlusion is crucial for stent failure prevention.

Risk of Complications and Restenosis

The global venous stents market is facing some complications due to the risk of complications and restenosis, which instigate questions regarding the long-term effectiveness and safety of venous stenting procedures. Even though there has been technological advancement in stents, barriers such as stent thrombosis, infection, or re-narrowing of the vein still exist and might lead to further procedures, prolonged recovery, or some surgical intervention. This fear sometimes turns out towards the patient or even the healthcare provider and sometimes does not consider venous stents as an option. Hence, it has a rather slow adoption rate and limits overall market potential. This stems the emergence and acceptance of venous stests in the healthcare industry.

For more details on this report - Request for Sample

Segment Analysis

The global venous stents market is segmented based on product type, material, application end user and region.

Product Type:

Covered Stents from the device segment is expected to dominate the Venous Stents market share

The covered stents segment holds a major portion of the venous stents market share and is expected to continue to hold a significant portion of the venous stents market share during the forecast period.

Covered stents are a vital segment in the global market for venous stents, by offering further protection from restenosis and other complications. Covered stents differ from bare metal stents in that their luminal surfaces are lined with a synthetic material to physically restrict tissue ingrowth, thereby reducing the risk of thrombosis, preventing re-narrowing of a vein. Thus they can be ideal for use in complicated situations, such as stenosis of large veins, or those susceptible to occlusion. In fact, covered stents are often preferred in high-risk patients due to the better long-term patency and likelihood of re-treatment.

For instance, in October 2023, Getinge has launched its iCast covered stent system for treating iliac arterial occlusive disease in the US, having received FDA premarket approval in March 2023. The balloon expandable polytetrafluoroethylene-covered stent is marketed outside the US as Advanta V12, according to Getinge.

End User:-

Hospitals segment is the fastest-growing segment in Venous Stents market share

The oncology segment is the fastest-growing segment in the venous stents market share and is expected to hold the market share over the forecast period.

Hospitals are the major healthcare providers in the global venous stents market by offering interventional radiology, vascular surgery, and cardiology in specialty services. Hospitals provide infrastructure and medical expertise for safe stent implantation by proper patient selection and post-procedural care. The increasing number of patients diagnosed with venous conditions has become a demand driver for venous stenting procedures, such as chronic venous insufficiency and deep vein thrombosis. Hospitals also train patients and physicians on the advantages and disadvantages of stenting. With the adoption of advanced stenting technologies, it can contribute to the market growth and acceptance of such forms of treatment.

Geographical Analysis

North America is expected to hold a significant position in the Venous Stents market share

North America holds a substantial position in the venous stents market and is expected to hold most of the market share due to advanced healthcare infrastructure accompanied by increasing prevalence of venous diseases such as DVT and CVI. Moreover, product launches, ongoing studies, demand for advanced treatment solutions is complemented by the geriatric population and alarming obesity statistics helps in the region growth. The sophisticated reimbursement mechanisms and the forceful active market players are conducive to a stimulating atmosphere for the development of innovative stent technologies while increased awareness channels between minimally invasive treatment options.

For instance, in March 2023, W. L. Gore & Associates has enrolled the first U.S. patient in a prospective, non-randomized, multicenter, single-arm study to evaluate the GORE VIAFORT Vascular Stent for treating symptomatic inferior Vena Cava obstruction with or without combined Iliofemoral Obstruction.

Hence, W. L. Gore & Associates is ongoing clinical trials on the GORE VIAFORT Vascular Stent, aiming to improve treatment options for venous obstructions and stimulate market growth by validating new therapeutic approaches and improving patient care outcomes.

Europe is growing at the fastest pace in the Venous Stents market

Europe holds the fastest pace in the venous stents market and is expected to hold most of the market share due to launches of significant products, healthcare expenditures, and development in the medical technology field. Hence, these factors drive the venous market for stents in Europe. Other factors that will drive the market include an aging population, government programs for chronic diseases, and the progress of clinical trials. A highly systematized and organized health structure provides timely diagnosis and treatment, thus increasing the venous stent uptake in Europe.

For instance, in June 2024 Philips has successfully implanted the Duo Venous Stent System, an implantable medical device designed to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency, following premarket approval from the U.S. FDA.

Competitive Landscape

The major global players in the venous stents market include Medtronic Plc, Boston Scientific Corporation, Cook Medical, Terumo Corporation, Becton, Dickinson and Company (BD), Abbott Laboratories, Cordis Corporation(Cardinal Health), Vesper Medical, Bentley, Optimed Medizinische Instrumente GmbH and among others.

Key Developments

  • In April 2024, Getinge has received EU MDR certification for its Advanta V12 covered stent system, which is used for patients with aortoiliac occlusive disease, including aortic bifurcation lesions. This certification confirms the system's compliance with EU regulations and reflects Getinge's commitment to quality and patient safety.
  • In July 2023, Steven Abramowitz, MD, at MedStar Washington Hospital Center, completed the first deep venous stent thrombosis procedures using a minimally invasive thrombectomy catheter, RevCore, which received FDA clearance in March and was officially launched in June. The stent cleaner is a deep venous "stent cleaner."

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global venous stents market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Material Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Material
  • 3.3. Snippet by Applications
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Risk of Complications and Restenosis
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Covered Stents*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Self-Expanding Stents
  • 6.4. Balloon-Expandable Stents
  • 6.5. Bare Stents

7. By Material

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 7.1.2. Market Attractiveness Index, By Material
  • 7.2. Nitinol*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Metal Stents
  • 7.4. Stainless Steel
  • 7.5. Polymers
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Deep Vein Thrombosis (DVT)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Chronic Venous Insufficiency (CVI)
  • 8.4. Pulmonary Embolism (PE)
  • 8.5. Tumor Occlusion
  • 8.6. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Ambulatory Surgical Centers

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Medtronic Plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Boston Scientific Corporation
  • 12.3. Cook Medical
  • 12.4. Terumo Corporation
  • 12.5. Becton, Dickinson and Company (BD)
  • 12.6. Abbott Laboratories
  • 12.7. Cordis Corporation(Cardinal Health)
  • 12.8. Vesper Medical
  • 12.9. Bentley
  • 12.10. Optimed Medizinische Instrumente GmbH
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. Endologix*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Medi-Globe
  • 12.13. Aortic Ltd
  • 12.14. Intra-Op
  • 12.15. Jotec GmbH
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us